These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2288719)

  • 21. The combination of stem cell transplantation and immunotherapy: future potential.
    Talmadge JE
    In Vivo; 1994; 8(5):675-90. PubMed ID: 7727713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer.
    Ayre SG; Garcia y Bellon DP; Garcia DP
    Med Hypotheses; 2000 Oct; 55(4):330-4. PubMed ID: 11000062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Established data and practical recommendations concerning pre- and postoperative chemotherapy of rectal cancer].
    Rougier P; Mitry E; Clavéro-Fabri MC; Penna C; Nordlinger B
    Ann Chir; 1999; 53(10):1011-8. PubMed ID: 10670150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer therapy with combinations of biological response modifiers and cytotoxics: an update.
    Borden EC; Creekmore SP
    Cancer Cells; 1990 Jul; 2(7):217-20. PubMed ID: 2204387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.
    Dicko A; Mayer LD; Tardi PG
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1329-41. PubMed ID: 21118030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Primary chemotherapy in operable breast carcinoma].
    Bonadonna G; Valagussa P
    Ann Ital Chir; 1999; 70(3):359-69. PubMed ID: 10466239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in chemotherapy for colorectal cancer.
    Bernold DM; Sinicrope FA
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):808-21. PubMed ID: 16797250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The present state of development of cancer chemotherapy.
    Ziegler JL
    Fed Proc; 1979 Jan; 38(1):97-102. PubMed ID: 365587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy.
    Zhou H; Sequeira M; Goad ME; Erickson J; Wong A; Clark E; Dunussi-Joannopoulos K; Li RC; Friedrich S; Hayes LL; Wolf SF
    Clin Immunol; 2001 Dec; 101(3):303-14. PubMed ID: 11726223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy as part of combinations for the treatment of cancer.
    Mitchell MS
    Int Immunopharmacol; 2003 Aug; 3(8):1051-9. PubMed ID: 12860162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
    Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
    Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curative and palliative aspects of regional chemotherapy in combination with surgery.
    Müller H; Hilger R
    Support Care Cancer; 2003 Jan; 11(1):1-10. PubMed ID: 12527948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of antiangiogenic therapy with other modalities.
    O'Reilly MS
    Cancer J; 2002; 8 Suppl 1():S89-99. PubMed ID: 12075706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma.
    Worth LL; Jaffe N; Benjamin RS; Papadopoulos NE; Patel S; Raymond AK; Jia SF; Rodriguez C; Gano J; Gianan MA; Kleinerman ES
    Clin Cancer Res; 1997 Oct; 3(10):1721-9. PubMed ID: 9815556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biotherapy of solid tumors].
    Moiseenko VM
    Vopr Onkol; 1998; 44(1):120-5. PubMed ID: 9578746
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.